CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Aurobindo Pharma Ltd (Parent) is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Aurobindo Pharma Ltd (Parent)
Water Mark Building,, Plot No. 11
Survey no.9, Kondapur, Hitech City
Phone: +91 4066725000p:+91 4066725000 HYDERABAD, 500084  India Fax: +91 4023741080f:+91 4023741080

Business Summary
Aurobindo Pharma Limited is a pharmaceutical company. The Company is engaged in producing oral and injectable generic formulations and active pharmaceutical ingredients (APIs). Its product portfolio is spread over seven therapeutic/product areas, including antibiotics, anti-retrovirals, cardiovascular, central nervous system, gastroenterologicals, anti-allergies and anti-diabetics. It is engaged in developing a range of oncology and hormonal products. It is also developing inhalation and dermatology products, such as pressurized metered-dose inhaler (pMDI). It markets its products through chain stores in the United States. It has developed over three injectable penem products. The Company, through its subsidiary, manufactures and sells nutritional supplements. It has over 10 manufacturing units and approximately two research and development centers. The Company, in addition to marketing its products domestically, also markets its products globally in over 150 countries.
(Source: ARS)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
IRA CQ
Score
Moody's
Rating
Fitch
Rating
DBRS
Rating
Morningstar
Rating
YesYes-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
9/30/20193/31/2019Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Non-Executive Independent Chairman of the Board K.Ragunathan 56 6/1/2012 1/30/2008
Whole-Time Vice Chairman of the Board, a promoter of the Company K. NityanandaReddy 61 6/1/2012
Chief Financial Officer SanthanamSubramanian 7/1/2014 7/1/2014
9 additional Officers and Directors records available in full report.

Business Names
Business Name
Aurobindo Pharma Limited (Parent)
Aurobindo Pharma USA Inc.
GENERIS Farmacêutica, S.A.
Natrol, Inc.
Silicon Life Sciences

General Information
Number of Employees: 8,635 (As of 3/31/2012)
Outstanding Shares: 585,900,000 (As of 9/30/2019)
Shareholders: 92,229
Fax Number: +91 4023741080


Copyright © 2019 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, December 12, 2019